ArrowMark Colorado Holdings’s CG Oncology CGON Stock Holding History

ArrowMark Colorado Holdings’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11M	Sell	155,354 -30,958	-17%	-$2.02M	0.46%	71
2026 Q1	$12.6M	Sell	186,312 -59,520	-24%	-$3.37M	0.34%	89
2025 Q4	$10.2M	Sell	245,832 -11,398	-4%	-$472K	0.22%	131
2025 Q3	$10.4M	Sell	257,230 -35,776	-12%	-$1.04M	0.19%	131
2025 Q2	$7.62M	Buy	293,006 +57,812	+25%	+$1.39M	0.14%	156
2025 Q1	$5.76M	Buy	235,194 +10,612	+5%	+$299K	0.09%	166
2024 Q4	$6.44M	Sell	224,582 -5,808	-3%	-$199K	0.09%	172
2024 Q3	$8.69M	Buy	230,390 +34,131	+17%	+$1.2M	0.11%	150
2024 Q2	$6.2M	Buy	196,259 +152	+0.1%	+$5.27K	0.07%	183
2024 Q1	$8.61M	Buy	+196,107	New	+$8.01M	0.1%	164

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ArrowMark Colorado Holdings's CGON Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its CG Oncology (CGON) stake by 17% in Q2 2026, selling an estimated $2.02M and leaving 155,354 shares worth $11M. The position accounts for 0.46% of the portfolio, ranked #71.

ArrowMark Colorado Holdings first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.6M in Q1 2026. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

ArrowMark Colorado Holdings held 155,354 shares of CG Oncology worth $11M as of Q2 2026.
ArrowMark Colorado Holdings sold 30,958 CG Oncology shares in Q2 2026, an estimated $2.02M.
CG Oncology made up 0.46% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #71 holding.
ArrowMark Colorado Holdings first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
ArrowMark Colorado Holdings's CG Oncology position peaked at $12.6M in Q1 2026.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.